MCID: ADR009
MIFTS: 40

Adrenal Cortex Disease

Categories: Endocrine diseases

Aliases & Classifications for Adrenal Cortex Disease

MalaCards integrated aliases for Adrenal Cortex Disease:

Name: Adrenal Cortex Disease 12 14
Adrenal Cortex Diseases 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3952
MeSH 41 D000303
SNOMED-CT 64 129636003
UMLS 69 C0001614

Summaries for Adrenal Cortex Disease

MalaCards based summary : Adrenal Cortex Disease, also known as adrenal cortex diseases, is related to primary pigmented nodular adrenocortical disease and acute adrenal insufficiency. An important gene associated with Adrenal Cortex Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are G alpha (s) signalling events and Corticotropin-releasing hormone signaling pathway. The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include adrenal cortex, cortex and adrenal gland, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Situated along the perimeter of the adrenal gland, the adrenal cortex mediates the stress response... more...

Related Diseases for Adrenal Cortex Disease

Diseases related to Adrenal Cortex Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 primary pigmented nodular adrenocortical disease 31.3 PDE11A POMC PRKAR1A
2 acute adrenal insufficiency 10.5 POMC REN
3 suprasellar meningioma 10.5 POMC REN
4 inappropriate adh syndrome 10.5 POMC REN
5 acth deficiency, isolated 10.5 CRH POMC
6 bronchus adenoma 10.4 POMC SST
7 bronchial adenomas/carcinoids childhood 10.4 POMC SST
8 acidophil adenoma 10.4 POMC SST
9 allergic urticaria 10.4 CRH NR3C1
10 hypoaldosteronism 10.4 CYP11B2 POMC REN
11 familial glucocorticoid deficiency 10.4 NR0B1 POMC REN
12 hypoadrenalism 10.4 CRH POMC
13 gonadal disease 10.4 CRH NR0B1 POMC
14 urinary system disease 10.4 CRH POMC REN
15 postural hypotension 10.4 REN SST
16 adrenal rest tumor 10.4 CYP11B1 CYP11B2 POMC
17 arthrogryposis, distal, type 3 10.3 NR3C2 REN
18 mental depression 10.3 CRH NR3C1 POMC
19 persistent fetal circulation syndrome 10.3 CRH HSD11B2 POMC
20 hormone producing pituitary cancer 10.3 PRKAR1A SST
21 adrenal cortical adenoma 10.3 CYP11B1 POMC PRKAR1A
22 chronic fatigue syndrome 10.3 CRH NR3C1 POMC
23 pituitary carcinoma 10.3 CRH POMC SST
24 fasting hypoglycemia 10.3 CRH POMC
25 ectopic cushing syndrome 10.3 CRH POMC SST
26 pseudohypoaldosteronism, type i, autosomal dominant 10.3 NR3C2 REN
27 corticosteroid-binding globulin deficiency 10.3 HSD11B2 NR3C1 POMC
28 mood disorder 10.3 CRH NR3C1 POMC
29 adenohypophysitis 10.2 POMC PRL
30 glucose metabolism disease 10.2 POMC REN SST
31 pseudohyperkalemia, familial, 2, due to red cell leak 10.2 CYP11B2 NR3C2 REN
32 lipoid congenital adrenal hyperplasia 10.2 CYP11B1 CYP11B2 POMC REN
33 pituitary apoplexy 10.2 POMC PRL
34 aldosterone-producing adenoma 10.2 CYP11B2 KCNJ5 REN
35 sella turcica neoplasm 10.2 POMC PRL
36 anuria 10.2 HSD11B2 NR3C2 REN
37 familial hyperaldosteronism 10.1 CYP11B1 CYP11B2 KCNJ5
38 tuberculum sellae meningioma 10.1 POMC PRL
39 steroid inherited metabolic disorder 10.1 CYP11B1 HSD11B2 POMC REN
40 hypothalamic disease 10.1 CRH POMC PRL
41 sheehan syndrome 10.1 CRH POMC PRL
42 congestive heart failure 10.1 CYP11B2 NR3C2 REN
43 adrenocortical carcinoma, hereditary 10.1 CYP11B1 CYP11B2 NR0B1 PRKAR1A
44 melancholia 10.1 CRH PRL
45 empty sella syndrome 10.1 POMC PRL
46 amenorrhea 10.1 CRH POMC PRL
47 tsh producing pituitary tumor 10.1 PRL SST
48 hypopituitarism 10.1 CRH POMC PRL
49 bulimia nervosa 2 10.1 CRH POMC PRL
50 multiple endocrine neoplasia, type iv 10.1 PRKAR1A PRL

Graphical network of the top 20 diseases related to Adrenal Cortex Disease:



Diseases related to Adrenal Cortex Disease

Symptoms & Phenotypes for Adrenal Cortex Disease

MGI Mouse Phenotypes related to Adrenal Cortex Disease:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 PRL REN PDE11A POMC SST PRKAR1A
2 homeostasis/metabolism MP:0005376 10.22 PRL REN POMC SST PRKAR1A CYP11B2
3 cardiovascular system MP:0005385 10.13 NR3C2 REN POMC PRKAR1A CYP11B1 CYP11B2
4 growth/size/body region MP:0005378 10.13 PRKAR1A NR3C2 REN SST POMC NR3C1
5 endocrine/exocrine gland MP:0005379 10.11 PRL POMC PRKAR1A CYP11B1 CYP11B2 AIRE
6 immune system MP:0005387 10.02 PRKAR1A PRL REN SST POMC NR3C1
7 liver/biliary system MP:0005370 9.87 PRL POMC PRKAR1A CYP11B2 AIRE CRH
8 nervous system MP:0003631 9.85 PRL PDE11A REN POMC SST NR3C2
9 neoplasm MP:0002006 9.73 PRKAR1A PRL POMC AIRE HSD11B2 NR0B1
10 no phenotypic analysis MP:0003012 9.43 SST POMC NR3C1 AIRE HSD11B2 CRH
11 renal/urinary system MP:0005367 9.23 REN POMC CYP11B1 CYP11B2 NR3C2 HSD11B2

Drugs & Therapeutics for Adrenal Cortex Disease

Drugs for Adrenal Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
6
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
10 insulin Phase 3,Phase 2
11 Insulin, Globin Zinc Phase 3,Phase 2
12 Mitogens Phase 3,Phase 2
13 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Hormonal Phase 3,Phase 2
17 Etoposide phosphate Phase 3,Phase 2
18 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
19 Antiemetics Phase 3,Phase 2
20 Anti-Inflammatory Agents Phase 3,Phase 2
21 Autonomic Agents Phase 3,Phase 2,Phase 1
22 BB 1101 Phase 3,Phase 2,Phase 1
23 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
24 Gastrointestinal Agents Phase 3,Phase 2
25 glucocorticoids Phase 3,Phase 2
26 HIV Protease Inhibitors Phase 3,Phase 2
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
31
protease inhibitors Phase 3,Phase 2
32
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Epinephrine Approved, Vet_approved Phase 2,Phase 1 51-43-4 5816
35 Racepinephrine Approved Phase 2,Phase 1 329-65-7
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 657311 5754
38
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
39
Etomidate Approved Phase 1, Phase 2 33125-97-2 667484 36339
40
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
41
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
42
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
43
Tamoxifen Approved Phase 2 10540-29-1 2733526
44
Suramin Approved, Investigational Phase 2,Phase 1 145-63-1 5361
45
nivolumab Approved Phase 2,Phase 1 946414-94-4
46
Pembrolizumab Approved Phase 2 1374853-91-4
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
48
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
49
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
50
acetic acid Approved, Nutraceutical Phase 2 64-19-7 176

Interventional clinical trials:

(show top 50) (show all 66)

# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Recruiting NCT01504555 Phase 3
5 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
6 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
7 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
8 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 Completed NCT02150213 Phase 2 BGG492
9 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
10 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
11 A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
12 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
13 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
14 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
15 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
17 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
18 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
19 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
21 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
22 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
23 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
24 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
27 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
28 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
29 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
30 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Active, not recruiting NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
31 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Not yet recruiting NCT03257891 Phase 2 Cabazitaxel
32 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
33 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
34 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
35 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
36 Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery Completed NCT01839812 Phase 1 Cosyntropin
37 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
38 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
39 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
40 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
41 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
42 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting NCT02637531 Phase 1 IPI-549;Nivolumab
43 Possible New Therapy for Advanced Cancer Terminated NCT01832974 Phase 1 IL-13-PE
44 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
45 The Effects of Case Management in a Medicaid Managed Care Plan Unknown status NCT00385879
46 Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC) Completed NCT00668291
47 Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma Completed NCT00768365
48 Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Completed NCT02015026
49 Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Completed NCT01528956
50 Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Completed NCT00445718

Search NIH Clinical Center for Adrenal Cortex Disease

Cochrane evidence based reviews: adrenal cortex diseases

Genetic Tests for Adrenal Cortex Disease

Anatomical Context for Adrenal Cortex Disease

MalaCards organs/tissues related to Adrenal Cortex Disease:

38
Adrenal Cortex, Cortex, Adrenal Gland, Testes, Liver, Bone

Publications for Adrenal Cortex Disease

Articles related to Adrenal Cortex Disease:

# Title Authors Year
1
Hypertension and adrenal cortex disease. A review of 100 autopsied cases. ( 5491407 )
1970

Variations for Adrenal Cortex Disease

Expression for Adrenal Cortex Disease

Search GEO for disease gene expression data for Adrenal Cortex Disease.

Pathways for Adrenal Cortex Disease

GO Terms for Adrenal Cortex Disease

Biological processes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.84 CRH HSD11B2 REN SST
2 steroid metabolic process GO:0008202 9.72 CRH CYP11B1 CYP11B2
3 female pregnancy GO:0007565 9.69 CRH HSD11B2 PRL
4 regulation of blood pressure GO:0008217 9.63 CYP11B1 POMC REN
5 steroid biosynthetic process GO:0006694 9.61 CYP11B1 CYP11B2 NR0B1
6 steroid hormone mediated signaling pathway GO:0043401 9.58 NR0B1 NR3C1 NR3C2
7 sterol metabolic process GO:0016125 9.57 CYP11B1 CYP11B2
8 adrenal gland development GO:0030325 9.56 CRH NR0B1
9 hypothalamus development GO:0021854 9.52 CRH NR0B1
10 C21-steroid hormone biosynthetic process GO:0006700 9.49 CYP11B1 CYP11B2
11 cellular response to potassium ion GO:0035865 9.48 CYP11B1 CYP11B2
12 hormone-mediated apoptotic signaling pathway GO:0008628 9.37 CRH SST
13 cortisol biosynthetic process GO:0034651 9.32 CYP11B1 CYP11B2
14 aldosterone biosynthetic process GO:0032342 9.26 CYP11B1 CYP11B2
15 regulation of blood volume by renal aldosterone GO:0002017 9.16 CYP11B2 HSD11B2
16 response to immobilization stress GO:0035902 9.13 CRH NR0B1 REN
17 glucocorticoid biosynthetic process GO:0006704 8.8 CRH CYP11B1 HSD11B2

Molecular functions related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.5 NR0B1 NR3C1 NR3C2
2 steroid binding GO:0005496 9.43 HSD11B2 NR3C1 NR3C2
3 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
4 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2
5 hormone activity GO:0005179 8.92 CRH POMC PRL SST

Sources for Adrenal Cortex Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....